Tevogen Bio Holdings Inc. - Common Stock TVGN 深 滬
等待開盤 09-29 09:30:00 美东时间
0.7963
+0.011
+1.44%
華盛通- 最 高0.8046
- 今 開0.8046
- 成交量 30.20万股
- 最 低 0.7631
- 昨 收 0.785
- 總市值 1.57亿
- 52周最高 3.09
- 市盈率 靜 --
- 換手率 0.15%
- 52周最低 0.2556
- 委 比 -64.91%
- 總股本 1.97亿
- 歷史最高 21.09
- 量 比 0.47
- 振 幅 5.29%
- 歷史最低 0.2556
- 每 手 1
- 風險率 2.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
Tevogen's PredicTcell™ platform, developed with Microsoft and Databricks, has expanded its training dataset to ~1.4 million and total dataset to over 6.7 billion records. This significant increase aims to enhance precision in identifying virology targets, potentially making T-cell therapies nearly 100% accurate. The expansion includes analyzing over 10.7 billion data points and increasing model features from 22 to 27. These advancements could rev...
09-25 12:30
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
Tevogen highlights emerging evidence linking persistent viral reservoirs to Long COVID and presents its investigational precision T cell therapy, TVGN 489, as a potential treatment. Studies show residual SARS-CoV-2 proteins and RNA persist long after infection, contributing to chronic inflammation and Long COVID symptoms. TVGN 489, targeting multiple SARS-CoV-2 proteins, demonstrated efficacy in reducing viral load and maintaining CTL persistence...
09-23 12:30
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
Tevogen thanks the U.S. Department of Health and Human Services for addressing the Long COVID crisis through roundtables. With approximately 20 million Americans affected, Tevogen highlights its investigational drug, TVGN 489, which shows promise in early trials. CEO Ryan Saadi and Board member Curtis Patton express optimism about the drug's potential to help Long COVID patients. Tevogen remains committed to advancing personalized therapies via i...
09-19 19:40
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
<p>Mittul Mehta, Tevogen’s Chief Information Officer and Head of Tevogen.AI, will join the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025. The event will take place at the Sheraton Boston Hotel. Mehta will discuss Tevogen.AI’s use of advanced data and AI technologies, including the PredicTcell™ platform developed with Microsoft and Databricks, to advance precision immunotherapy. Other panelists include Chris Gervais of Co...
09-10 15:59
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
Tevogen announced that the risk-adjusted net present value (rNPV) for its pipeline product TVGN 116 in the US is estimated to exceed $325 million. TVGN 116, designed for liver cancer prevention in high-risk chronic Hepatitis B patients, has a 5-year revenue forecast of approximately $6.5 billion. The company highlighted its innovative, cost-efficient drug development model and progress with TVGN 489, demonstrating rapid milestone achievements. Th...
09-09 19:15
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
Tevogen announced its allogeneic precision T cell therapy, TVGN-489, targeting high-risk COVID-19 and Long-COVID patients, with a risk-adjusted net present value of $9 to $11 billion. Phase I trials showed rapid viral elimination, no severe side effects, and durable immune response. The company plans to provide further updates on its product pipeline and valuation.
09-08 13:27
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
Tevogen Bio Holdings Inc. announced that its pipeline product TVGN 930 for treating non-solid tumor malignancies caused by the Epstein-Barr Virus (EBV) has a risk-adjusted Net Present Value (rNPV) exceeding ~$250 million in the US. The product targets five rare disease indications, with a potential market of up to 40,000 patients. It aims to improve outcomes for patients with hematologic malignancies. The 5-year revenue forecast for TVGN 930 is ~...
09-04 19:48
Tevogen Highlights Clinical Data For TVGN 489, A T Cell Therapy Targeting COVID-19 In Immunocompromised Patients
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune systems, who are at the highest risk of complications
09-04 04:17
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
Tevogen highlights the need for SARS-CoV-2 treatments for immunocompromised individuals, introducing TVGN 489, an allogeneic CTL immunotherapy targeting the viral genome. Clinical trial data shows >99% viral elimination by day 14, faster symptom resolution, and no disease progression or Long COVID. TVGN 489 is unaffected by mutations, including the XFG variant. Experts emphasize the importance of immune support for vulnerable populations year-rou...
09-03 20:15
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
Tevogen updated investors on its internally developed assets, which under U.S. GAAP are not reflected on its balance sheet but represent long-term value. Key assets include intellectual property (3 granted U.S. patents and 12 pending, including 2 in AI), drug development platforms (ExacTcell™), AI collaborations with Microsoft and Databricks (PredicTcell™ and AdapTcell™), a clinical pipeline targeting cancers, strong cash reserves, and facilities...
08-27 19:20
